US20020013315A1 - Gamma secretase inhibitors - Google Patents
Gamma secretase inhibitors Download PDFInfo
- Publication number
- US20020013315A1 US20020013315A1 US09/896,296 US89629601A US2002013315A1 US 20020013315 A1 US20020013315 A1 US 20020013315A1 US 89629601 A US89629601 A US 89629601A US 2002013315 A1 US2002013315 A1 US 2002013315A1
- Authority
- US
- United States
- Prior art keywords
- compound according
- alkyl
- pharmaceutically acceptable
- alkoxycarbonyl
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003540 gamma secretase inhibitor Substances 0.000 title description 4
- 150000001875 compounds Chemical class 0.000 claims abstract description 37
- 150000003839 salts Chemical class 0.000 claims abstract description 12
- 108010070047 Notch Receptors Proteins 0.000 claims abstract description 11
- 230000011664 signaling Effects 0.000 claims abstract description 10
- 208000024827 Alzheimer disease Diseases 0.000 claims abstract description 9
- 229910052760 oxygen Inorganic materials 0.000 claims abstract description 5
- 102000005650 Notch Receptors Human genes 0.000 claims abstract 2
- 238000000034 method Methods 0.000 claims description 13
- -1 hydroxy, amino Chemical group 0.000 claims description 9
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 7
- 229910052736 halogen Inorganic materials 0.000 claims description 7
- 150000002367 halogens Chemical class 0.000 claims description 7
- 125000001424 substituent group Chemical group 0.000 claims description 6
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 5
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 claims description 5
- 229910052739 hydrogen Inorganic materials 0.000 claims description 5
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 239000001301 oxygen Chemical group 0.000 claims description 4
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 3
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims description 3
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 claims description 3
- OFLXXYUJIPXYLS-UHFFFAOYSA-N 2-[[2-(3,5-difluorophenyl)acetyl]amino]-n-[2-oxo-1-phenyl-2-[(4-phenylmorpholin-2-yl)methylamino]ethyl]propanamide Chemical compound C1N(C=2C=CC=CC=2)CCOC1CNC(=O)C(C=1C=CC=CC=1)NC(=O)C(C)NC(=O)CC1=CC(F)=CC(F)=C1 OFLXXYUJIPXYLS-UHFFFAOYSA-N 0.000 claims description 3
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 3
- 125000003320 C2-C6 alkenyloxy group Chemical group 0.000 claims description 3
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims description 2
- 125000004916 (C1-C6) alkylcarbonyl group Chemical group 0.000 claims description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 2
- 239000005864 Sulphur Chemical group 0.000 claims description 2
- 125000005078 alkoxycarbonylalkyl group Chemical group 0.000 claims description 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 2
- 239000001257 hydrogen Substances 0.000 claims description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 2
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 2
- 150000003573 thiols Chemical class 0.000 claims 3
- 102000002659 Amyloid Precursor Protein Secretases Human genes 0.000 abstract description 7
- 108010043324 Amyloid Precursor Protein Secretases Proteins 0.000 abstract description 7
- 230000002265 prevention Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 description 19
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 12
- 101710137189 Amyloid-beta A4 protein Proteins 0.000 description 10
- 101710151993 Amyloid-beta precursor protein Proteins 0.000 description 10
- 102100022704 Amyloid-beta precursor protein Human genes 0.000 description 10
- 102000014736 Notch Human genes 0.000 description 9
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 239000002552 dosage form Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- 0 C[C@H](NC(=O)Cc1cc(F)cc(F)c1)C(=O)NC(C(=O)NCC1*CCN([Ar])C1)c1ccccc1 Chemical compound C[C@H](NC(=O)Cc1cc(F)cc(F)c1)C(=O)NC(C(=O)NCC1*CCN([Ar])C1)c1ccccc1 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 239000006187 pill Substances 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 125000006239 protecting group Chemical group 0.000 description 4
- 230000002797 proteolythic effect Effects 0.000 description 4
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 3
- 239000007995 HEPES buffer Substances 0.000 description 3
- 108010036933 Presenilin-1 Proteins 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 239000012909 foetal bovine serum Substances 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- MFBOGIVSZKQAPD-UHFFFAOYSA-M sodium butyrate Chemical compound [Na+].CCCC([O-])=O MFBOGIVSZKQAPD-UHFFFAOYSA-M 0.000 description 3
- 125000003396 thiol group Chemical class [H]S* 0.000 description 3
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 2
- JMTMSDXUXJISAY-UHFFFAOYSA-N 2H-benzotriazol-4-ol Chemical compound OC1=CC=CC2=C1N=NN2 JMTMSDXUXJISAY-UHFFFAOYSA-N 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
- 102400000552 Notch 1 intracellular domain Human genes 0.000 description 2
- 101800001628 Notch 1 intracellular domain Proteins 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 102000012412 Presenilin-1 Human genes 0.000 description 2
- 241000269370 Xenopus <genus> Species 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 239000007900 aqueous suspension Substances 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 239000012055 enteric layer Substances 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000017854 proteolysis Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- YAKKATWFMLCGMI-UHFFFAOYSA-N (4-phenylmorpholin-2-yl)methanamine Chemical compound C1COC(CN)CN1C1=CC=CC=C1 YAKKATWFMLCGMI-UHFFFAOYSA-N 0.000 description 1
- 230000006269 (delayed) early viral mRNA transcription Effects 0.000 description 1
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
- 125000004211 3,5-difluorophenyl group Chemical group [H]C1=C(F)C([H])=C(*)C([H])=C1F 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000037259 Amyloid Plaque Diseases 0.000 description 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 1
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 1
- 108010048112 Amyloidogenic Proteins Proteins 0.000 description 1
- 102000009091 Amyloidogenic Proteins Human genes 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 230000007082 Aβ accumulation Effects 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 102100022033 Presenilin-1 Human genes 0.000 description 1
- 108010050254 Presenilins Proteins 0.000 description 1
- 102000015499 Presenilins Human genes 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 241000269368 Xenopus laevis Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 229940081735 acetylcellulose Drugs 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 108010064397 amyloid beta-protein (1-40) Proteins 0.000 description 1
- 108010064539 amyloid beta-protein (1-42) Proteins 0.000 description 1
- 230000006933 amyloid-beta aggregation Effects 0.000 description 1
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229940090047 auto-injector Drugs 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000008436 biogenesis Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004744 butyloxycarbonyl group Chemical group 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 239000007822 coupling agent Substances 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 210000005220 cytoplasmic tail Anatomy 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 239000012054 flavored emulsion Substances 0.000 description 1
- 235000020375 flavoured syrup Nutrition 0.000 description 1
- 108091007739 gamma-secretases Proteins 0.000 description 1
- 102000038383 gamma-secretases Human genes 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- ZEKANFGSDXODPD-UHFFFAOYSA-N glyphosate-isopropylammonium Chemical compound CC(C)N.OC(=O)CNCP(O)(O)=O ZEKANFGSDXODPD-UHFFFAOYSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-M methanesulfonate group Chemical class CS(=O)(=O)[O-] AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229920001206 natural gum Polymers 0.000 description 1
- 210000002682 neurofibrillary tangle Anatomy 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000012053 oil suspension Substances 0.000 description 1
- 150000003891 oxalate salts Chemical class 0.000 description 1
- 239000003182 parenteral nutrition solution Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 239000008024 pharmaceutical diluent Substances 0.000 description 1
- 229960003424 phenylacetic acid Drugs 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000004237 preparative chromatography Methods 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 210000002023 somite Anatomy 0.000 description 1
- 239000001593 sorbitan monooleate Substances 0.000 description 1
- 235000011069 sorbitan monooleate Nutrition 0.000 description 1
- 229940035049 sorbitan monooleate Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 150000003892 tartrate salts Chemical class 0.000 description 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Definitions
- the present invention relates to compounds, their salts, pharmaceutical compositions comprising them, processes for making them and their use in treating Alzheimer's Disease.
- AD Alzheimer's Disease
- the rate of amyloid accumulation is a combination of the rates of formation, aggregation and egress from the brain. It is generally accepted that the main constituent of amyloid plaques is the 4 kD amyloid protein ( ⁇ A4, also referred to as A ⁇ , ⁇ -protein and ⁇ AP) which is a proteolytic product of a precursor protein of much larger size.
- ⁇ A4 also referred to as A ⁇ , ⁇ -protein and ⁇ AP
- the ragged NH 2 - and COOH-termini of the native A ⁇ amyloid indicates that a complex mechanism of proteolysis is involved in its biogenesis.
- amyloid precursor protein (APP or A ⁇ PP) has a receptor-like structure with a large ectodomain, a membrane spanning region and a short cytoplasmic tail.
- Different isoforms of APP result from the alternative splicing of three exons in a single gene and have 695,751 and 770 amino acids respectively.
- the A ⁇ domain encompasses parts of both extra-cellular and transmembrane domains of APP, thus its release implies the existence of two distinct proteolytic events to generate its NH 2 - and COOH-termini. At least two secretory mechanisms exist which release APP from the membrane and generate the soluble, COOH-truncated forms of APP (APPs). Proteases which release APP and its fragments from the membrane are termed “secretases”. Most APPs is released by a putative ⁇ -secretase which cleaves within the A ⁇ domain (between residues Lys 16 and Leu 17 ) to release ( ⁇ -APPs and precludes the release of intact A ⁇ .
- a minor portion of APPs is released by a ⁇ -secretase, which cleaves near the NH 2 -terminus of A ⁇ and produces COOH-terminal fragments (CTFs) which contain the whole A ⁇ domain. Finding these fragments in the extracellular compartment suggests that another proteolytic activity ( ⁇ -secretase) exists under normal conditions which can generate the COOH-terminus of A ⁇ .
- ⁇ secretase inhibitors to inhibit the functioning of presinilins, which have been proposed as candidates ⁇ secretases, has raised questions over their suitability.
- signalling through the Notch pathway important during embryonic development and in haematopoeisis, requires the presenilin-dependent proteolytic release of the Notch intracellular domain (NICD).
- Notch intracellular domain NBD
- the present invention provides a compound of formula I or a pharmaceutically acceptable salt thereof:
- X is CH 2 , oxygen or sulphur
- Ar is phenyl optionally substituted by one, two or three substituents chosen from halogen, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, hydroxy, cyano, nitro, NR 1 R 2 where R 1 and R 2 are independently hydrogen or C 1-6 alkyl, C 1-6 alkoxy, C 2-6 alkenyloxy, C 2-6 alkynyloxy, thiol, C 1-6 alkylthio, C 2-6 alkenylthio, C 2-6 alkynylthio, C 1-6 alkylcarbonyl, C 1-6 alkoxycarbonyl, C 1-6 haloalkyl, C 2-6 haloalkenyl and C 2-6 haloalkynyl.
- X is oxygen
- Ar is optionally substituted by one, two or three substituents chosen from halogen, C 1-6 alkyl, hydroxy, amino, C 1-6 alkoxy, thiol, C 1-6 alkoxycarbonyl and C 1-6 haloalkyl.
- Ar is optionally substituted by one substituent chosen from halogen, C 1-4 alkyl, hydroxy, amino, C 1-4 alkoxy, thiol, C 1-4 alkoxycarbonyl and C 1-4 haloalkyl.
- Ar is unsubstituted.
- a specific Example of the present invention is: 2-[2-(3,5-difluorophenyl)acetylamino]-N- ⁇ phenyl[(4-phenylmorpholin-2-ylmethyl)carbamoyl]methyl ⁇ propionamide and the pharmaceutically acceptable salts thereof.
- C 1-6 alkyl includes methyl and ethyl groups, and straight-chained and branched propyl, butyl, pentyl and hexyl groups. Particular alkyl groups are methyl, ethyl, n-propyl, isopropyl and t-butyl. Derived expressions such as “C 1-4 alkyl”, “C 2-6 alkenyl” and “C 2-6 alkynyl” are to be construed in an analogous manner.
- halogen as used herein includes fluorine, chlorine, bromine and iodine, of which fluorine and chlorine are preferred.
- C 1-6 alkoxy includes methoxy and ethoxy groups, and straight-chained, branched and cyclic propoxy and butoxy groups, including cyclopropylmethoxy.
- C 2-6 alkynyloxy “C 2-6 alkenyloxy”, “C 1-6 alkylthio”, “C 2-6 alkenylthio”, “C 2-6 alkynylthio” and “C 1-4 alkoxy” are to be construed in analogous manner.
- C 1-6 alkoxycarbonyl includes methoxycarbonyl and alkoxycarbonyl groups and straight-chained, branched and cyclic propoxycarbonyl and butoxycarbonyl groups, including cyclopropylmethoxycarbonyl. “C 1-4 alkoxycarbonyl” is to be construed in analogous manner.
- Examples of pharmaceutically acceptable salts are hydrochlorides, sulfates, citrates, tartrates, acetates, methanesulfonates, phosphates, oxalates and benzoates.
- the compounds of the present invention have an activity as inhibitors of ⁇ secretase.
- the compounds of the invention inhibit proteolysis of PS-1.
- compositions comprising one or more compounds of this invention and a pharmaceutically acceptable carrier.
- these compositions are in unit dosage forms such as tablets, pills, capsules, powders, granules, sterile parenteral solutions or suspensions, metered aerosol or liquid sprays, drops, ampoules, transdermal patches, auto-injector devices or suppositories; for oral, parenteral, intranasal, sublingual or rectal administration, or for administration by inhalation or insufflation.
- a pharmaceutical carrier e.g.
- This solid preformulation composition is then subdivided into unit dosage forms of the type described above containing from 0.1 to about 500 mg of the active ingredient of the present invention.
- Typical unit dosage forms contain from 1 to 100 mg, for example 1, 2, 5, 10, 25, 50 or 100 mg, of the active ingredient.
- the tablets or pills of the novel composition can be coated or otherwise compounded to provide a dosage form affording the advantage of prolonged action.
- the tablet or pill can comprise an inner dosage and an outer dosage component, the latter being in the form of an envelope over the former.
- the two components can be separated by an enteric layer which serves to resist disintegration in the stomach and permits the inner component to pass intact into the duodenum or to be delayed in release.
- enteric layers or coatings such materials including a number of polymeric acids and mixtures of polymeric acids with such materials as shellac, cetyl alcohol and cellulose acetate.
- the present invention also provides a compound of the invention or a pharmaceutically acceptable salt thereof for use in a method of treatment of the human body.
- the treatment is for a condition associated with the deposition of ⁇ -amyloid.
- the condition is a neurological disease having associated ⁇ -amyloid deposition such as Alzheimer's disease.
- this treatment occurs without inhibiting Notch signalling.
- the present invention further provides the use of a compound of the present invention or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating or preventing Alzheimer's disease, preferably without inhibiting Notch signalling.
- This method of treatment preferably does not inhibit Notch signalling.
- a suitable dosage level is about 0.01 to 250 mg/kg per day, preferably about 0.01 to 100 mg/kg per day, and especially about 0.01 to 5 mg/kg of body weight per day.
- the compounds may be administered on a regimen of 1 to 4 times per day. In some cases, however, dosage outside these limits may be used.
- X and Ar are as defined above, generally in the presence of a coupling agent such as 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide, and hydroxybenzotriazole, generally in the presence of a base such as triethylamine, and a solvent such as tetrahydrofuran, for about 18 h at room temperature.
- a coupling agent such as 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide, and hydroxybenzotriazole
- a typical assay which can be used to determine the level of activity of compounds of the present invention is as follows:
- redox dye reduction To determine if compounds are cytotoxic cell viability following compound administration is assessed by the use of redox dye reduction.
- a typical example is a combination of redox dye MTS (Promega) and the electron coupling reagent PES. This mixture is made up according to the manufacturer's instructions and left at room temperature.
- the Example of the present invention had an ED 50 of less than 500 nM in the above assay.
- Xenopus embryos were cultured in ⁇ fraction (1/10) ⁇ NAM [Beck & Slack, Development, 126, 1611-1620, 1999] supplemented with protease inhibitors (200 ⁇ stock in DMSO) from stage 15 [P. D. Nieuwkoop and J. Faber, Normal table of Xenopus laevis, Daudin 1967, Reprinted Garland 1994] (24 hours), to stage 40 (3 days).
- Control siblings were incubated in ⁇ fraction (1/10) ⁇ NAM containing 0.05% DMSO. At 3 days they were fixed in batches of 20 and measured using a graduated eyepiece on a Wild dissecting microscope set to 25 ⁇ .
- Example of the present invention did not significantly inhibit tail bud formation.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
- The present invention relates to compounds, their salts, pharmaceutical compositions comprising them, processes for making them and their use in treating Alzheimer's Disease.
- Alzheimer's Disease (AD) is characterized by the abnormal deposition of amyloid in the brain in the form of extra-cellular plaques and intra-cellular neurofibrillary tangles. The rate of amyloid accumulation is a combination of the rates of formation, aggregation and egress from the brain. It is generally accepted that the main constituent of amyloid plaques is the 4 kD amyloid protein (βA4, also referred to as Aβ,β-protein and βAP) which is a proteolytic product of a precursor protein of much larger size. The ragged NH2- and COOH-termini of the native Aβ amyloid indicates that a complex mechanism of proteolysis is involved in its biogenesis.
- The amyloid precursor protein (APP or AβPP) has a receptor-like structure with a large ectodomain, a membrane spanning region and a short cytoplasmic tail. Different isoforms of APP result from the alternative splicing of three exons in a single gene and have 695,751 and 770 amino acids respectively.
- The Aβ domain encompasses parts of both extra-cellular and transmembrane domains of APP, thus its release implies the existence of two distinct proteolytic events to generate its NH2- and COOH-termini. At least two secretory mechanisms exist which release APP from the membrane and generate the soluble, COOH-truncated forms of APP (APPs). Proteases which release APP and its fragments from the membrane are termed “secretases”. Most APPs is released by a putative α-secretase which cleaves within the Aβdomain (between residues Lys16 and Leu17) to release (α-APPs and precludes the release of intact Aβ. A minor portion of APPs is released by a β-secretase, which cleaves near the NH2-terminus of Aβ and produces COOH-terminal fragments (CTFs) which contain the whole Aβ domain. Finding these fragments in the extracellular compartment suggests that another proteolytic activity (γ-secretase) exists under normal conditions which can generate the COOH-terminus of Aβ.
- It is believed that γ secretase itself depends for its activity on the presence of presenilin-1. In a manner that is not fully understood presenilin-1 appears to undergo autocleavage.
- The potential of γ secretase inhibitors to inhibit the functioning of presinilins, which have been proposed as candidates γ secretases, has raised questions over their suitability. In particular, signalling through the Notch pathway, important during embryonic development and in haematopoeisis, requires the presenilin-dependent proteolytic release of the Notch intracellular domain (NICD). Using a novel Xenopus developmental assay for Notch activity it has surprisingly been found that the present γ secretase inhibitors do not prevent Notch signalling in-vivo.
- The present compounds are structurally related to those disclosed in WO-A-9822494. However there is no discussion in that document of the problem of interference of Notch signalling nor any suggestion of how the provision of γ-secretase inhibitors that do not inhibit Notch signalling may be achieved.
-
- wherein: X is CH2, oxygen or sulphur; and
- Ar is phenyl optionally substituted by one, two or three substituents chosen from halogen, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, hydroxy, cyano, nitro, NR1R2 where R1 and R2 are independently hydrogen or C1-6alkyl, C1-6alkoxy, C2-6alkenyloxy, C2-6alkynyloxy, thiol, C1-6alkylthio, C2-6alkenylthio, C2-6alkynylthio, C1-6alkylcarbonyl, C1-6alkoxycarbonyl, C1-6haloalkyl, C2-6haloalkenyl and C2-6haloalkynyl.
- Preferably X is oxygen.
- Preferably Ar is optionally substituted by one, two or three substituents chosen from halogen, C1-6alkyl, hydroxy, amino, C1-6alkoxy, thiol, C1-6alkoxycarbonyl and C1-6haloalkyl.
- More preferably Ar is optionally substituted by one substituent chosen from halogen, C1-4alkyl, hydroxy, amino, C1-4alkoxy, thiol, C1-4alkoxycarbonyl and C1-4haloalkyl.
- In one embodiment Ar is unsubstituted.
- A specific Example of the present invention is: 2-[2-(3,5-difluorophenyl)acetylamino]-N-{phenyl[(4-phenylmorpholin-2-ylmethyl)carbamoyl]methyl}propionamide and the pharmaceutically acceptable salts thereof.
- As used herein, the expression “C1-6alkyl” includes methyl and ethyl groups, and straight-chained and branched propyl, butyl, pentyl and hexyl groups. Particular alkyl groups are methyl, ethyl, n-propyl, isopropyl and t-butyl. Derived expressions such as “C1-4alkyl”, “C2-6alkenyl” and “C2-6alkynyl” are to be construed in an analogous manner.
- The term “halogen” as used herein includes fluorine, chlorine, bromine and iodine, of which fluorine and chlorine are preferred.
- As used herein the term “C1-6alkoxy” includes methoxy and ethoxy groups, and straight-chained, branched and cyclic propoxy and butoxy groups, including cyclopropylmethoxy. “C2-6alkynyloxy”, “C2-6alkenyloxy”, “C1-6alkylthio”, “C2-6alkenylthio”, “C2-6alkynylthio” and “C1-4alkoxy” are to be construed in analogous manner.
- As used herein the term “C1-6alkoxycarbonyl” includes methoxycarbonyl and alkoxycarbonyl groups and straight-chained, branched and cyclic propoxycarbonyl and butoxycarbonyl groups, including cyclopropylmethoxycarbonyl. “C1-4alkoxycarbonyl” is to be construed in analogous manner.
- Examples of pharmaceutically acceptable salts are hydrochlorides, sulfates, citrates, tartrates, acetates, methanesulfonates, phosphates, oxalates and benzoates.
- The compounds of the present invention have an activity as inhibitors of γsecretase. In a preferred embodiment the compounds of the invention inhibit proteolysis of PS-1.
- The invention also provides pharmaceutical compositions comprising one or more compounds of this invention and a pharmaceutically acceptable carrier. Preferably these compositions are in unit dosage forms such as tablets, pills, capsules, powders, granules, sterile parenteral solutions or suspensions, metered aerosol or liquid sprays, drops, ampoules, transdermal patches, auto-injector devices or suppositories; for oral, parenteral, intranasal, sublingual or rectal administration, or for administration by inhalation or insufflation. For preparing solid compositions such as tablets, the principal active ingredient is mixed with a pharmaceutical carrier, e.g. conventional tableting ingredients such as corn starch, lactose, sucrose, sorbitol, talc, stearic acid, magnesium stearate, dicalcium phosphate or gums or surfactants such as sorbitan monooleate, polyethylene glycel, and other pharmaceutical diluents, e.g. water, to form a solid preformulation composition containing a homogeneous mixture of a compound of the present invention, or a pharmaceutically acceptable salt thereof. When referring to these preformulation compositions as homogeneous, it is meant that the active ingredient is dispersed evenly throughout the composition so that the composition may be readily subdivided into equally effective unit dosage forms such as tablets, pills and capsules. This solid preformulation composition is then subdivided into unit dosage forms of the type described above containing from 0.1 to about 500 mg of the active ingredient of the present invention. Typical unit dosage forms contain from 1 to 100 mg, for example 1, 2, 5, 10, 25, 50 or 100 mg, of the active ingredient. The tablets or pills of the novel composition can be coated or otherwise compounded to provide a dosage form affording the advantage of prolonged action. For example, the tablet or pill can comprise an inner dosage and an outer dosage component, the latter being in the form of an envelope over the former. The two components can be separated by an enteric layer which serves to resist disintegration in the stomach and permits the inner component to pass intact into the duodenum or to be delayed in release. A variety of materials can be used for such enteric layers or coatings, such materials including a number of polymeric acids and mixtures of polymeric acids with such materials as shellac, cetyl alcohol and cellulose acetate.
- The present invention also provides a compound of the invention or a pharmaceutically acceptable salt thereof for use in a method of treatment of the human body. Preferably the treatment is for a condition associated with the deposition of β-amyloid. Preferably the condition is a neurological disease having associated β-amyloid deposition such as Alzheimer's disease. Preferably this treatment occurs without inhibiting Notch signalling.
- The present invention further provides the use of a compound of the present invention or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating or preventing Alzheimer's disease, preferably without inhibiting Notch signalling.
- Also disclosed is a method of treatment of a subject suffering from or prone to Alzheimer's disease which comprises administering to that subject an effective amount of a compound according to the present invention or a pharmaceutically acceptable salt thereof. This method of treatment preferably does not inhibit Notch signalling.
- The liquid forms in which the novel compositions of the present invention may be incorporated for administration orally or by injection include aqueous solutions, suitably flavored syrups, aqueous or oil suspensions, and flavored emulsions with edible oils such as cottonseed oil, sesame oil, coconut oil or peanut oil, as well as elixirs and similar pharmaceutical vehicles. Suitable dispersing or suspending agents for aqueous suspensions include synthetic and natural gums such as tragacanth, acacia, alginate, dextran, sodium carboxymethylcellulose, methylcellulose, polyvinyl-pyrrolidone or gelatin.
- For treating or preventing Alzheimer's Disease, a suitable dosage level is about 0.01 to 250 mg/kg per day, preferably about 0.01 to 100 mg/kg per day, and especially about 0.01 to 5 mg/kg of body weight per day. The compounds may be administered on a regimen of 1 to 4 times per day. In some cases, however, dosage outside these limits may be used.
-
- wherein X and Ar are as defined above, generally in the presence of a coupling agent such as 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide, and hydroxybenzotriazole, generally in the presence of a base such as triethylamine, and a solvent such as tetrahydrofuran, for about 18 h at room temperature.
- Compounds of formulae II and III are commercially available or can be made by known methods from commercially available compounds.
- It will be understood that any compound of formula I initially obtained from the above process may, where appropriate, subsequently be elaborated into a further compound of formula I by techniques known from the art.
- It will also be appreciated that where more than one isomer can be obtained from a reaction then the resulting mixture of isomers can be separated by conventional means.
- Where the above-described process for the preparation of the compounds according to the invention gives rise to mixtures of stereoisomers, these isomers may be separated by conventional techniques such as preparative chromatography. The novel compounds may be prepared in racemic form, or individual enantiomers may be prepared either by enantiospecific synthesis or by resolution.
- During any of the above synthetic sequences it may be necessary and/or desirable to protect sensitive or reactive groups on any of the molecules concerned. This may be achieved by means of conventional protecting groups, such as those described inProtective Groups in Organic Chemistry, ed. J. F. W. McOmie, Plenum Press, 1973; and T. W. Greene & P. G. M. Wuts, Protective Groups in Organic Synthesis, John Wiley & Sons, 1991. The protecting groups may be removed at a convenient subsequent stage using methods known from the art.
- A typical assay which can be used to determine the level of activity of compounds of the present invention is as follows:
- (1) Mouse neuroblastoma neuro 2a cells expressing human app695 are cultured at 50-70% confluency in the presence of sterile 10 mM sodium butyrate.
- (2) Cells are placed in 96-well plates at 30,000/well/100 μL in minimal essential medium (MEM) (phenol red-free)+10% foetal bovine serum (FBS), 5mM HEPES buffer (pH7.3), 1% glutamine, 0.2 mg/mL G418 antibiotic, 10 mM sodium butyrate.
- (3) Make dilutions of the compound plate. Dilute stock solution to 5.5% DMSO/110 μM compound. Mix compounds vigorously and store at 4° C. until use.
- (4) Add 10 μL compound/well. Mix plate briefly, and leave for 18 h in 37° C. incubator.
- (5) Remove 90 μL of culture supernatant and dilute 1:1 with ice-cold 25mM HEPES (pH.3), 0.1% BSA, 1.0 mM EDTA (+broad spectrum protease inhibitor cocktail; pre-aliquotted into a 96-well plate). Mix and keep on ice or freeze at -80° C.
- (6) Add back 100 μL of warm MEM +10% FBS, 50 mM HEPES (pH7.3), 1% glutamine, 0.2 mg/mL G418, 10 mM sodium butyrate to each well, and return plate to 37° C. incubator.
- (7) Prepare reagents necessary to determine amyloid peptide levels, for example by ELISA assay
- (8) To determine if compounds are cytotoxic cell viability following compound administration is assessed by the use of redox dye reduction. A typical example is a combination of redox dye MTS (Promega) and the electron coupling reagent PES. This mixture is made up according to the manufacturer's instructions and left at room temperature.
- (9) Quantitate amyloid beta 40 and 42 peptides using an appropriate volume of diluted culture medium by standard ELISA techniques.
- (10) Add 15 μL/well MTS/PES solution to the cells; mix and leave at 37° C.
- (11) Read plate when the absorbance values are approximately 1.0 (mix briefly before reading to disperse the reduced formazan product).
- The Example of the present invention had an ED50 of less than 500 nM in the above assay.
- The following assay was used to determine the effect of compounds on Notch signalling.
- Xenopus embryos were cultured in {fraction (1/10)} NAM [Beck & Slack, Development, 126, 1611-1620, 1999] supplemented with protease inhibitors (200× stock in DMSO) from stage 15 [P. D. Nieuwkoop and J. Faber, Normal table of Xenopus laevis, Daudin 1967, Reprinted Garland 1994] (24 hours), to stage 40 (3 days). Control siblings were incubated in {fraction (1/10)} NAM containing 0.05% DMSO. At 3 days they were fixed in batches of 20 and measured using a graduated eyepiece on a Wild dissecting microscope set to 25×. Each tadpole was measured from head to proctodaeum (head and trunk) and from proctodaeum to tail tip (tail). Tail buds were extirpated at stage 30 and cultured for 24 hours as described previously [Tucker & Slack, Development, 121, 249-262, 1995]. Somites were detected by staining with monoclonal antibody 12/101 [Kintner & Brockes, Nature, 308, 67-69, 1984], as described elsewhere [Tucker & Slack, 1995]. In situ hybridisation for Xhox3 has been previously described [Beck & Slack, Mech. Dev., 72, 41-52, 1998].
- The Example of the present invention did not significantly inhibit tail bud formation.
- The following Examples illustrate the present invention.
- 2-[2-(3,5-Difluorophenyl)acetylamino]-N-{phenyl[(4-phenylmorpholin-2-ylmethyl)carbamoyl]methyl}propionamide
- A mixture of [(3,5-Difluorophenyl)acetylamino]-1-ethylcarbamoyl-1-phenyl ethanoic acid (20 mg, 0.053 mmol), 1-(3-dimethylaminopropyl)-3-ethyl carbodiimide (11.2 mg, 0.058 mmol) and hydroxybenzotriazole (7.8 mg, 0.058 mmol) in tetrahydrofuran was treated with N-phenyl 2-aminomethyl morpholine (15.2 mg, 0.079 mmol) and triethylamine (16 mg, 0.159 mmol) and the reaction stirred for 18 hours at room temperature. Evaporation of the solvent and purification on a bond elute cartridge gave the product (6 mg). Mixture of diastereoisomers: (1H, DMSO) 8.45-8.34 (3 H, m), 7.43-6.76 (10 H, m), 5.44 (1 H, t), 4.44 (1 H, t), 3.91 (1 H, br), 3.59-3.16 (11 H, m), 2.61 (1 H, dd), 2.26 (1 H,m), 1.22 (3 H, m) MS (CI+) MH+551.
Claims (9)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0016681.9A GB0016681D0 (en) | 2000-07-06 | 2000-07-06 | Therapeutic compounds |
GB0016681 | 2000-07-06 | ||
GB0016681.9 | 2000-07-06 |
Publications (2)
Publication Number | Publication Date |
---|---|
US20020013315A1 true US20020013315A1 (en) | 2002-01-31 |
US6448229B2 US6448229B2 (en) | 2002-09-10 |
Family
ID=9895191
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/896,296 Expired - Fee Related US6448229B2 (en) | 2000-07-06 | 2001-06-29 | Gamma secretase inhibitors |
Country Status (2)
Country | Link |
---|---|
US (1) | US6448229B2 (en) |
GB (1) | GB0016681D0 (en) |
Cited By (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020133159A1 (en) * | 2000-12-08 | 2002-09-19 | Jackson Roger P. | Closure for open-headed medical implant |
US20040167526A1 (en) * | 2002-09-06 | 2004-08-26 | Roger P. Jackson | Closure for rod receiving orthopedic implant having left handed thread removal |
US20040172032A1 (en) * | 2002-09-06 | 2004-09-02 | Jackson Roger P. | Anti-splay medical implant closure with multi-surface removal aperture |
US20040199164A1 (en) * | 2002-09-06 | 2004-10-07 | Jackson Roger P. | Helical wound mechanically interlocking mating guide and advancement structure |
US20050182410A1 (en) * | 2002-09-06 | 2005-08-18 | Jackson Roger P. | Helical guide and advancement flange with radially loaded lip |
US20050232927A1 (en) * | 2004-02-03 | 2005-10-20 | The Regents Of The University Of Michigan | Compositions and methods for characterizing, regulating, diagnosing, and treating cancer |
US20060009773A1 (en) * | 2002-09-06 | 2006-01-12 | Jackson Roger P | Helical interlocking mating guide and advancement structure |
US20060241603A1 (en) * | 2003-06-18 | 2006-10-26 | Jackson Roger P | Polyaxial bone screw assembly with fixed retaining structure |
US20060252073A1 (en) * | 2005-04-18 | 2006-11-09 | Regents Of The University Of Michigan | Compositions and methods for the treatment of cancer |
US20070078099A1 (en) * | 2003-02-27 | 2007-04-05 | Mclaurin Joanne | Method of preventing, treating and diagnosing disorders of protein aggregation |
US20080019961A1 (en) * | 2006-02-21 | 2008-01-24 | Regents Of The University Of Michigan | Hedgehog signaling pathway antagonist cancer treatment |
US20080178305A1 (en) * | 2000-08-03 | 2008-07-24 | The Regents Of The University Of Michigan | Isolation And Use Of Solid Tumor Stem Cells |
US20090163498A1 (en) * | 2002-11-18 | 2009-06-25 | Chemocentryx, Inc. | Aryl Sulfonamides |
US20100016904A1 (en) * | 2003-06-18 | 2010-01-21 | Jackson Roger P | Upload shank swivel head bone screw spinal implant |
US7723112B2 (en) | 2005-10-31 | 2010-05-25 | The Regents Of The University Of Michigan | Compositions and methods for treating and diagnosing cancer |
US20100211114A1 (en) * | 2003-06-18 | 2010-08-19 | Jackson Roger P | Polyaxial bone anchor with shelf capture connection |
US20100318136A1 (en) * | 2003-06-18 | 2010-12-16 | Jackson Roger P | Polyaxial bone screw assembly |
EP2369014A1 (en) | 2004-02-03 | 2011-09-28 | The Regents Of The University Of Michigan Office Of Technology Transfer | Compositions and methods for characterizing, regulating, diagnosing and treating cancer |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6191166B1 (en) * | 1997-11-21 | 2001-02-20 | Elan Pharmaceuticals, Inc. | Methods and compounds for inhibiting β-amyloid peptide release and/or its synthesis |
US6984522B2 (en) | 2000-08-03 | 2006-01-10 | Regents Of The University Of Michigan | Isolation and use of solid tumor stem cells |
WO2003032994A2 (en) * | 2001-10-17 | 2003-04-24 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Novel tri-substituted pyrimidines, method for production and use thereof as medicament |
PT2500360E (en) | 2005-10-31 | 2015-10-15 | Oncomed Pharm Inc | Compositions and methods for diagnosing and treating cancer |
US7723477B2 (en) | 2005-10-31 | 2010-05-25 | Oncomed Pharmaceuticals, Inc. | Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth |
US9567396B2 (en) | 2006-03-07 | 2017-02-14 | Evonik Degussa Gmbh | Notch inhibition in the prevention of vein graft failure |
WO2011053822A2 (en) | 2009-11-01 | 2011-05-05 | The Brigham And Women's Hospital, Inc. | Notch inhibition in the treatment and prevention of obesity and metabolic syndrome |
US8133857B2 (en) * | 2006-03-07 | 2012-03-13 | The Brigham and Women's FHospital, Inc. | NOTCH inhibition in the treatment of atherosclerosis |
JP5379692B2 (en) | 2006-11-09 | 2013-12-25 | プロビオドルグ エージー | 3-Hydroxy-1,5-dihydro-pyrrol-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcers, cancer and other diseases |
JP5523107B2 (en) | 2006-11-30 | 2014-06-18 | プロビオドルグ エージー | Novel inhibitors of glutaminyl cyclase |
US8148147B2 (en) | 2007-01-24 | 2012-04-03 | The Regents Of The University Of Michigan | Compositions and methods for treating and diagnosing pancreatic cancer |
ZA200905537B (en) | 2007-03-01 | 2010-10-27 | Probiodrug Ag | New use of glutaminyl cyclase inhibitors |
JP5667440B2 (en) | 2007-04-18 | 2015-02-12 | プロビオドルグ エージー | Thiourea derivatives as glutaminyl cyclase inhibitors |
SG190568A1 (en) | 2008-09-26 | 2013-06-28 | Oncomed Pharm Inc | Frizzled-binding agents and uses thereof |
US20120129189A1 (en) * | 2009-07-17 | 2012-05-24 | Chulan Kwon | Methods of Controlling Cell Proliferation |
US8486940B2 (en) | 2009-09-11 | 2013-07-16 | Probiodrug Ag | Inhibitors |
TWI535445B (en) | 2010-01-12 | 2016-06-01 | 安可美德藥物股份有限公司 | Wnt antagonists and methods of treatment and screening |
WO2011107530A2 (en) | 2010-03-03 | 2011-09-09 | Probiodrug Ag | Novel inhibitors |
KR101790806B1 (en) | 2010-03-10 | 2017-11-20 | 프로비오드룩 아게 | Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5) |
JP2013530929A (en) | 2010-04-01 | 2013-08-01 | オンコメッド ファーマシューティカルズ インコーポレイテッド | Frizzled binders and uses thereof |
WO2011131748A2 (en) | 2010-04-21 | 2011-10-27 | Probiodrug Ag | Novel inhibitors |
ES2570167T3 (en) | 2011-03-16 | 2016-05-17 | Probiodrug Ag | Benzimidazole derivatives as glutaminyl cyclase inhibitors |
US9629891B2 (en) | 2011-10-17 | 2017-04-25 | Nationwide Children's Hospital, Inc. | Products and methods for aortic abdominal aneurysm |
CA2887711A1 (en) | 2012-10-23 | 2014-05-01 | Oncomed Pharmaceuticals, Inc. | Methods of treating neuroendocrine tumors using wnt pathway-binding agents |
US9359444B2 (en) | 2013-02-04 | 2016-06-07 | Oncomed Pharmaceuticals Inc. | Methods and monitoring of treatment with a Wnt pathway inhibitor |
US9168300B2 (en) | 2013-03-14 | 2015-10-27 | Oncomed Pharmaceuticals, Inc. | MET-binding agents and uses thereof |
DK3461819T3 (en) | 2017-09-29 | 2020-08-10 | Probiodrug Ag | GLUTAMINYL CYCLASE INHIBITORS |
US20210290633A1 (en) | 2018-07-19 | 2021-09-23 | INSERM (Insstitut National de la Santé et de la Recherche Médicale) | Combination for treating cancer |
EP4244391A1 (en) | 2020-11-16 | 2023-09-20 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for predicting and treating uveal melanoma |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR016751A1 (en) | 1996-11-22 | 2001-08-01 | Athena Neurosciences Inc | METHOD FOR INHIBITING THE RELEASE OF THE BETA-AMYLOID PEPTIDE IN A CELL, PHARMACEUTICAL COMPOSITION AND USEFUL COMPOUNDS IN THIS METHOD |
-
2000
- 2000-07-06 GB GBGB0016681.9A patent/GB0016681D0/en not_active Ceased
-
2001
- 2001-06-29 US US09/896,296 patent/US6448229B2/en not_active Expired - Fee Related
Cited By (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8044259B2 (en) | 2000-08-03 | 2011-10-25 | The Regents Of The University Of Michigan | Determining the capability of a test compound to affect solid tumor stem cells |
US8420885B2 (en) | 2000-08-03 | 2013-04-16 | The Regents Of The University Of Michigan | Determining the capability of a test compound to affect solid tumor stem cells |
US20080178305A1 (en) * | 2000-08-03 | 2008-07-24 | The Regents Of The University Of Michigan | Isolation And Use Of Solid Tumor Stem Cells |
US20020133159A1 (en) * | 2000-12-08 | 2002-09-19 | Jackson Roger P. | Closure for open-headed medical implant |
US20050182410A1 (en) * | 2002-09-06 | 2005-08-18 | Jackson Roger P. | Helical guide and advancement flange with radially loaded lip |
US20080039848A1 (en) * | 2002-09-06 | 2008-02-14 | Jackson Roger P | Anti-splay medical implant closure with multi-surface removal aperture |
US20060009773A1 (en) * | 2002-09-06 | 2006-01-12 | Jackson Roger P | Helical interlocking mating guide and advancement structure |
US20040199164A1 (en) * | 2002-09-06 | 2004-10-07 | Jackson Roger P. | Helical wound mechanically interlocking mating guide and advancement structure |
US20040167526A1 (en) * | 2002-09-06 | 2004-08-26 | Roger P. Jackson | Closure for rod receiving orthopedic implant having left handed thread removal |
US20090259259A1 (en) * | 2002-09-06 | 2009-10-15 | Jackson Roger P | Helical wound mechanically interlocking mating guide and advancement structure |
US20040172032A1 (en) * | 2002-09-06 | 2004-09-02 | Jackson Roger P. | Anti-splay medical implant closure with multi-surface removal aperture |
US9890148B2 (en) | 2002-11-18 | 2018-02-13 | Chemocentryx, Inc. | Aryl sulfonamides |
US20090163498A1 (en) * | 2002-11-18 | 2009-06-25 | Chemocentryx, Inc. | Aryl Sulfonamides |
US10364240B2 (en) | 2002-11-18 | 2019-07-30 | ChemoCentryx. Inc. | Aryl sulfonamides |
US9833420B2 (en) | 2003-02-27 | 2017-12-05 | JoAnne McLaurin | Methods of preventing, treating, and diagnosing disorders of protein aggregation |
US8859628B2 (en) | 2003-02-27 | 2014-10-14 | JoAnne McLaurin | Method for preventing, treating and diagnosing disorders of protein aggregation |
US20090227686A1 (en) * | 2003-02-27 | 2009-09-10 | Mclaurin Joanne | Methods of preventing, treating and diagnosing disorders of protein aggregation |
US20070078099A1 (en) * | 2003-02-27 | 2007-04-05 | Mclaurin Joanne | Method of preventing, treating and diagnosing disorders of protein aggregation |
US20060241603A1 (en) * | 2003-06-18 | 2006-10-26 | Jackson Roger P | Polyaxial bone screw assembly with fixed retaining structure |
US20100211114A1 (en) * | 2003-06-18 | 2010-08-19 | Jackson Roger P | Polyaxial bone anchor with shelf capture connection |
US20100318136A1 (en) * | 2003-06-18 | 2010-12-16 | Jackson Roger P | Polyaxial bone screw assembly |
US20100030280A1 (en) * | 2003-06-18 | 2010-02-04 | Jackson Roger P | Upload shank swivel head bone screw spinal implant |
US20100016904A1 (en) * | 2003-06-18 | 2010-01-21 | Jackson Roger P | Upload shank swivel head bone screw spinal implant |
EP2369014A1 (en) | 2004-02-03 | 2011-09-28 | The Regents Of The University Of Michigan Office Of Technology Transfer | Compositions and methods for characterizing, regulating, diagnosing and treating cancer |
US20080260734A1 (en) * | 2004-02-03 | 2008-10-23 | The Regents Of The University Of Michigan | Compositions and methods for characterizing, regulating, diagnosing, and treating cancer |
US20050232927A1 (en) * | 2004-02-03 | 2005-10-20 | The Regents Of The University Of Michigan | Compositions and methods for characterizing, regulating, diagnosing, and treating cancer |
US20060252073A1 (en) * | 2005-04-18 | 2006-11-09 | Regents Of The University Of Michigan | Compositions and methods for the treatment of cancer |
US7723112B2 (en) | 2005-10-31 | 2010-05-25 | The Regents Of The University Of Michigan | Compositions and methods for treating and diagnosing cancer |
US20080019961A1 (en) * | 2006-02-21 | 2008-01-24 | Regents Of The University Of Michigan | Hedgehog signaling pathway antagonist cancer treatment |
Also Published As
Publication number | Publication date |
---|---|
US6448229B2 (en) | 2002-09-10 |
GB0016681D0 (en) | 2000-08-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6448229B2 (en) | Gamma secretase inhibitors | |
US6984626B2 (en) | Gamma-secretase inhibitors | |
US6756511B2 (en) | Gamma-secretase inhibitors | |
US7157478B2 (en) | Oxadiazole derivatives for inhibition of gamma secretase | |
US7049296B2 (en) | Gamma-secretase inhibitors | |
TOMIYAMA et al. | Rifampicin inhibits the toxicity of pre-aggregated amyloid peptides by binding to peptide fibrils and preventing amyloid-cell interaction | |
JP2004531517A (en) | Sulfone regulating the action of γ-secretase | |
AU2017272151B2 (en) | Benzylideneguanidine derivatives and therapeutic use for the treatment of protein misfolding diseases | |
WO2003093253A1 (en) | Alkynyl-substituted spirocyclic sulfamides for the treatment of alzheimer's disease | |
US20030078240A1 (en) | Phosphinylmethyl and phosphorylmethyl succinic and glutaric acid analogs as beta-secretase inhibitors | |
HUT70408A (en) | 1-benzene-sulfonyl-1,3-dihydro-indol-2-one derivatives, process for producing them and pharmaceutical compositions containing them | |
KR20120112351A (en) | Opsin-binding ligands, compositions and methods of use | |
KR20110028554A (en) | O-substituted hydroxyaryl derivatives | |
EP1309585B1 (en) | Novel indole derivatives and their use as medicaments | |
DE60318317T2 (en) | ACYLAMINOTHIAZOL DERIVATIVES AND THEIR UTILIZATION AS BETA-AMYLOID INHIBITORS | |
IL92870A (en) | Substituted semicarbazones and their use as arthropodicides | |
US20110021471A1 (en) | REDUCING Abeta42 LEVELS AND Abeta AGGREGATION | |
EP0595183B1 (en) | Hydantoin derivatives, salts thereof and maillard reaction inhibitors comprising the same | |
EP3535239A1 (en) | Inhibitors of mtor-deptor interactions and methods of use thereof | |
PT809635E (en) | ALPHA-SUBSTITUTED HYDRAZINES WITH CALPAIN INHIBITING ACTIVITY | |
US5252592A (en) | Tetrazoleacetic acid derivatives having aldose reductase inhibitory activity | |
KR20010092424A (en) | Novel type condensed pyridazinone compounds | |
US20040248877A1 (en) | Polycyclic diazodioxide-based Bcl-2 protein antagonists and use thereof | |
Attia et al. | Research Article Anticonvulsant Potential of Certain New (2E)-2-[1-Aryl-3-(1H-imidazol-1-yl) propylidene]-N-(aryl/H) hydrazinecarboxamides | |
KR20080006384A (en) | Compounds for inhibiting p25 and process for preparing same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: SULZER SPINE-TECH INC., MINNESOTA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:HANSON, DAVID A.;LONGHINI, ROSS A.;SEME, STEVEN J.;REEL/FRAME:012449/0688;SIGNING DATES FROM 20011016 TO 20011022 |
|
AS | Assignment |
Owner name: MERCK SHARP & DOHME LTD., ENGLAND Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:TEALL, MARTIN RICHARD;REEL/FRAME:013116/0080 Effective date: 20010621 |
|
FPAY | Fee payment |
Year of fee payment: 4 |
|
FPAY | Fee payment |
Year of fee payment: 8 |
|
REMI | Maintenance fee reminder mailed | ||
LAPS | Lapse for failure to pay maintenance fees | ||
STCH | Information on status: patent discontinuation |
Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362 |
|
FP | Expired due to failure to pay maintenance fee |
Effective date: 20140910 |